<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538329</url>
  </required_header>
  <id_info>
    <org_study_id>11 253 01</org_study_id>
    <nct_id>NCT01538329</nct_id>
  </id_info>
  <brief_title>Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease</brief_title>
  <acronym>PREMANDYSK</acronym>
  <official_title>Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally amantadine is used at the beginning of Parkinson Disease (PD) treatment in the
      early stages of the disease, as a modest antiparkinsonian symptomatic treatment. This
      treatment is usually maintained for no more than the first few months of management, before
      resorting to drugs deemed more effective as dopamine agonists and lévo-DOPA (L-DOPA). A more
      modern use of the drug is at a more advanced stage of PD when dyskinesia are already
      established and become disabling for the patients. There is no data between these two
      extremes of life stages of Parkinsonism. However, the mechanisms of action of amantadine and
      the pathophysiology of the motor complications induced by L-DOPA, in particular dyskinesia
      suggest that the early and prolonged use of amantadine in the early years of management,
      before L-DOPA-induced dyskinesia have already emerged, should have a positive impact on
      long-term occurrence and fate of these symptoms, possibly through a glutamatergic mechanism
      of brain plasticity-of the &quot;disease modification&quot; type.

      The primary purpose of this study is to demonstrate that early introduction of treatment with
      amantadine (200 mg / d) in the early years of therapeutic care, that is to say during the
      &quot;honeymoon&quot; of levodopa (early phase of disease &lt;3 years of diagnosis &lt;1 year of L-dopa and
      lack of complications of levodopa therapy) decreases the rate of subjects with abnormal
      involuntary dyskinetic movements after 18 months of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>after 18 months of Phase 1 of the study</measure>
    <time_frame>after 18 months of follow-up</time_frame>
    <description>Rate of patient with abnormal involuntary dyskinetic movements (as specifically defined in the protocol) after 18 months of Phase 1 of the study (amantadine versus placebo).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out)</measure>
    <time_frame>22 months after inclusion</time_frame>
    <description>Rate of patients with abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motor fluctuations after 18 months of Phase 1 of the study</measure>
    <time_frame>18 months after inclusion</time_frame>
    <description>Rate of patients with non-motor fluctuations after 18 months of Phase 1 (defined by the specific scale developed by the Marseille team involved in the project)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of dyskinesias</measure>
    <time_frame>each visits</time_frame>
    <description>Time to onset of dyskinesias defined as the study visit at which the investigator answers &quot;yes&quot; for the first time the question &quot;do you think this patient has dyskinesia as defined in Protocol &quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with amantadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with amantadine placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>200mg / day once daily in the morning and at noon - oral administration -</description>
    <arm_group_label>Amantadine</arm_group_label>
    <other_name>active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>200mg / day once daily in the morning and at noon - oral administration -</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo of amantadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 35 years,

          -  Patients having signed an informed consent before any specific study procedures,

          -  Patients having a health Insurance Coverage (according to local regulatory
             requirements),

          -  Patients suffering from idiopathic Parkinson's disease meeting the definition criteria
             of the UKPD Brain Bank (Gibb and Lees, 1988),

          -  Parkinson's disease diagnosed for &lt;3 years,

          -  Patients receiving treatment with L-DOPA from &lt;1year,

          -  Lack of complications of levodopa therapy

          -  Patients receiving a stable antiparkinsonian treatment that may involve, in addition
             to L-DOPA, a dopamine agonist, a monoamine oxidase-B (MAO-B) or a catecholamine
             O-methyl transferase (COMT) inhibitor, an anti-cholinergic for at least 2 months
             before enrollment and in whom we presume it will be possible to maintain this
             treatment unchanged during the study period (except the dose of L-dopa which can be
             adjusted during the study after the third month of Phase 1).

        Exclusion Criteria:

          -  Atypical parkinsonian syndromes,

          -  Drug-induced Parkinsonism,

          -  Juvenile Parkinson,

          -  Patients with complications of levodopa therapy

          -  Inability to keep the current stable antiparkinsonian treatment during the study
             period, apart from L-DOPA,

          -  Pretreatment with amantadine,

          -  amantadine counter-indication

          -  Neuroleptic treatment,

          -  Patients with dementia, Mini Mental Status (MMS) &lt;26,

          -  Patient with behavioral disorder, ECMP item ≥ 3

          -  Female subjects of childbearing potential without effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Rascol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delphine VERNET</last_name>
    <phone>33-5 61 77 72 16</phone>
    <email>vernet.d@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHG Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Viallet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Tison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Jean Rougier</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marc Boulesteix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>franck Durif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maurice Giroud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain Destée, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frederic Torny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Broussolle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Philippe Azulay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Boulloche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Geny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHu de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Damier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Narbonne</name>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jany Rey Zermati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital pitié Salpétriére</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Corvol, MD</last_name>
      <phone>0142165773</phone>
      <email>jean-christophe.corvol@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Corvol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Luc Houeto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Maltête, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Tanchant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Rascol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyskinesia</keyword>
  <keyword>L-DOPA</keyword>
  <keyword>Early introduced treatment</keyword>
  <keyword>Amantadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

